Potassium Citrate
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Potassium Citrate: Familial visceral myopathy
One-Sentence Summary
Potassium citrate is an alkalinizing potassium salt. The TxGNN model predicts it may be effective for familial visceral myopathy, but this is a computational prediction only. No clinical trials and no publications in the data compiled for this report support this specific prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Familial visceral myopathy |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, potassium citrate is an oral alkalinizing agent and potassium source. It is used in conditions involving potassium loss or acid-base imbalance, and mechanistically it might be applicable to familial visceral myopathy only in a limited, supportive way.
Familial visceral myopathy is a genetic disorder of visceral smooth muscle, mainly affecting gut motility. No plausible mechanism connects potassium citrate to the underlying muscle pathology. The only conceivable link is symptomatic correction of low potassium (hypokalemia), which can impair gut motility.
The high TxGNN score (0.9995, model rank 1358) should therefore be read as a hypothesis generated by the model. It is not supported by any study of this disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
At least 20 valid licences for single-ingredient products are on record, and the list may be partial. The licence records do not include approved indication text. Five representative licences:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 174780 | Potrate 5 Tablet ER | Strip of 10 extended-release tablets | Not stated in licence record |
| 174035 | Potrate 10 Tablet ER | Strip of 10 extended-release tablets | Not stated in licence record |
| 230472 | Urofit Oral Solution | 300 ml bottle, oral solution | Not stated in licence record |
| 230308 | Urofit Oral Solution | 100 ml bottle, oral solution | Not stated in licence record |
| 86199 | Floblis Syrup | 200 ml bottle, syrup | Not stated in licence record |
Safety Considerations
- Contraindication relations recorded in the knowledge graph (not label text): hypertension, kidney disease and impaired renal function, anuria, adrenal insufficiency and Addison disease, peptic ulcer disease, pancreatitis, hypercalcemia, nephrocalcinosis, coronary artery disease and myocardial infarction, diarrheal disease, and metabolic acidosis, among others.
- Drug Interactions: 181 interactions are recorded. Major-level examples:
- Potassium-sparing diuretic: amiloride
- ACE inhibitor and ARBs: benazepril, olmesartan, valsartan
- Anticholinergics: atropine, hyoscyamine, homatropine, methscopolamine
- Antihistamines: chlorpheniramine, acrivastine, phenyltoloxamine
- Tricyclic antidepressant: amitriptyline
Moderate-level examples include NSAIDs (ibuprofen, ketorolac, aspirin), aliskiren, doxycycline, and the amphetamines and pseudoephedrine.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on the model score. There are no trials or publications on familial visceral myopathy, and no credible mechanism beyond possible correction of low potassium. The evidence level is L5.
To proceed, the following is needed:
- Any clinical or mechanistic study of potassium citrate in familial visceral myopathy or related visceral smooth muscle disorders
- Mechanism of action data
- Package insert warnings and contraindications from the India licence holders
- Confirmation of the approved indications in the licence records
It is a far stronger candidate and should be evaluated as a separate report. Cautions would include small trial sizes, possible promotion of calcium phosphate stones by higher urinary pH, and monitoring of potassium and renal function.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.